Ocumetics Technology Plans First In-human Trial After Successful Completion of Animal Study

TL;DR

Canadian company, Inn Edics Technology, completes a successful animal study for its innovative Edics accommodating lens, a major milestone towards commercialization.

Transcript

welcome to CEO insights I'm Marilyn dezman with Inn edics technology a Canadian based research and product development company has just announced the completion of the animal study for its innovative edics accommodating lens it's a key Milestone as the company progresses its product toward commercialization and here to talk about what this recent M... Read More

Key Insights

• 🤫 Edics Technology has completed a successful animal study for its accommodating lens, showing extremely favorable results compared to the control in cataract surgery.
• 🎨 Biocompatibility is crucial for FDA approval, and Edics has surpassed this threshold with its lens design.
• 😃 The lens utilizes the eye's natural biokinetics, allowing for distance, intermediate, and near vision without conscious effort.
• 😷 Edics plans to conduct its first inhuman study in early 2024 and pursue FDA approval through a well-defined process.
• 🧡 The company has a strong value proposition, including a wide accommodative amplitude range, quick accommodation and disaccommodation, and the absence of potentially toxic silicone oil.
• 😃 Investors can benefit from Edics' experienced leadership team, top advisors, and the large market potential in the eye care industry.

Questions & Answers

Q: What were the results of the animal study for Edics accommodating lens?

The results of the animal study were extremely favorable, with no animal deaths during the three-month period. The lens showed better results compared to the control device used in cataract surgery, indicating good biocompatibility.

Q: What were the goals of the animal study, besides biocompatibility?

The study aimed to assess postsurgical inflammation, opacification, and safety thresholds. The goal was to ensure that the lens not only had good biocompatibility but also performed well and met safety standards for future human studies.

Q: How does the Edics accommodating lens technology work?

The Edics lens uses the eye's natural biokinetics to provide distance, intermediate, and near vision without the need for conscious effort. It consists of two optical elements sandwiched with air, avoiding the use of potentially toxic silicone oil used by competitors.

Q: Why should investors consider working with Edics?

Edics has a strong team with decades of experience in the iare (intraocular) space. The company works closely with top advisors and medical research facilities. Additionally, the market potential for Edics accommodating lens is significant, with a large and growing population of potential candidates.

Summary & Key Takeaways

• Edics Technology has announced the completion of a three-month animal study for its accommodating lens, with extremely favorable results compared to existing control devices used in cataract surgery.

• The study focused on biocompatibility, postsurgical inflammation, and opacification, with the goal of passing the safety threshold for future human studies.

• The company plans to conduct its first inhuman study in early 2024, followed by a multicenter clinical trial and FDA approval process.